HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

John Ouyang Selected Research

Vasopressin Receptors (Arginine Vasopressin Receptor)

6/2015Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
6/2013Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
10/2011Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
8/2011Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
11/2008Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
3/2007Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


John Ouyang Research Topics

Disease

14Heart Failure
11/2015 - 06/2003
9Hyponatremia
11/2015 - 06/2003
6Autosomal Dominant Polycystic Kidney (ADPKD)
11/2015 - 08/2011
5Dyspnea (Shortness of Breath)
06/2013 - 03/2007
5Body Weight (Weight, Body)
07/2012 - 06/2003
4Edema
06/2011 - 06/2003
3Cysts
12/2012 - 08/2011
2Hypotension (Low Blood Pressure)
07/2012 - 12/2008
2Disease Progression
10/2011 - 08/2011
1Drug-Induced Liver Injury
11/2015
1Fibrosis (Cirrhosis)
11/2015
1Weight Loss (Weight Reduction)
06/2013
1Systolic Heart Failure
06/2013
1Pain (Aches)
12/2012
1Psychotic Disorders (Schizoaffective Disorder)
04/2012
1Hypertension (High Blood Pressure)
10/2011
1Polycystic Kidney Diseases (Polycystic Kidney Disease)
08/2011
1Polyuria
04/2010
1Fatigue
04/2010
1Schizophrenia (Dementia Praecox)
12/2008
1Cardiomyopathies (Cardiomyopathy)
03/2007
1Low Cardiac Output
12/2006
1Hypothermia
12/2006
1Hypokalemia
04/2004

Drug/Important Bio-Agent (IBA)

22tolvaptanFDA Link
11/2015 - 06/2003
17Vasopressins (Vasopressin)IBA
06/2013 - 06/2003
9SodiumIBA
06/2013 - 06/2003
6Vasopressin Receptors (Arginine Vasopressin Receptor)IBA
06/2015 - 03/2007
4DiureticsIBA
06/2013 - 04/2004
3CreatinineIBA
06/2015 - 12/2006
3Urea (Carbamide)FDA LinkGeneric
07/2012 - 12/2006
3NitrogenIBA
07/2012 - 12/2006
2TEMPOIBA
11/2015 - 10/2015
2ElectrolytesIBA
02/2006 - 04/2004
1Cyclic AMP (AMP, Cyclic)IBA
08/2011
1PotassiumIBA
02/2006